New research opens the door for more streamlined and patient-centric protocols, informed by benchmarking analysis of phase II and III protocol procedures PHILADELPHIA, Jan. 6, 2026 /PRNewswire/ -- ...

NetraMark Holdings ( ($TSE:AIAI) ) has provided an update. NetraMark reported a pivotal quarter marked by an expanded contract backlog to ...

Innovation in ophthalmology is often measured by what reaches the clinic—but the path to those breakthroughs begins much ...

Despite rapid growth, only 9.2% of DCTs are multiregional and over 80% single-country, indicating challenges in international implementation. 2 With regulatory agencies 4–7 underscoring risk-based ...

A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the studies’ key analyses, while also highlighting how an increase in clinical ...

ATLANTIC BEACH, Fla.--(BUSINESS WIRE)--nPhase, Inc., an innovator of cloud-based clinical research technology, today launched REDCap Cloud 2.0, the first industry platform to harmonize real-world ...

Early-phase clinical trials, those first-in-human studies, are where years of research and millions in investment meet the ...

Please provide your email address to receive an email when new articles are posted on . The meeting will take place June 21 in Las Vegas. Attendees will explore topics such as regulatory ...

Please provide your email address to receive an email when new articles are posted on . Use of decentralized elements in cancer clinical trials did not have long-term negative effects on data quality.

BioNTech will present significant clinical trial data at the prestigious ASCO Annual Meeting, highlighting the advancement of its diversified oncology portfolio. The preliminary results for BNT327 and ...

• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic ...